What Happened?
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 24% in the afternoon session after U.S. Food and Drug Administration (FDA) reported that the shortage of weight-loss drugs such as Wegovy and Ozempic has ended. This could lead to lower sales for companies like Hims & Hers Health, which sell weight-loss medications through their platform.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Hims & Hers Health? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Hims & Hers Health’s shares are extremely volatile and have had 73 moves greater than 5% over the last year. But moves this big are rare even for Hims & Hers Health and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 2 days ago when the stock gained 24.8% on the news that the company announced the acquisition of Sigmund (marketed as Trybe Labs), which will allow it to introduce home lab testing through its platform. This capability is expected to help its subscribers test and identify diseases with more accuracy. The data generated from these new features is expected to support AI initiatives like MedMatch, which aim to improve treatment recommendations.
Hims & Hers Health is up 98.9% since the beginning of the year, but at $50.15 per share, it is still trading 27% below its 52-week high of $68.74 from February 2025. Investors who bought $1,000 worth of Hims & Hers Health’s shares 5 years ago would now be looking at an investment worth $4,964.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.
